Submission of Statement of deviation / variation for the quarter ended 30th September, 2026

HEMO ORGANIC LIMITED CIN - L24231GJ1992PLC018224 Address: Shop 1 to 3, First floor, Piyu Apartment Opp Electricity Sub Station & Mahesh Nagar, Nr. Radhika Chambers & Jay Amarnath Society, Nikol Gam Road, Uttamnagar, Ahmedabad, Gujarat, India – 382 350 Email ID: hemoorganic@gmail.com Website: www.hemoorganic.co Ph. No. 8238557874 Date To, th : 17 October, 2026 BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001 Dear Sir/Ma’am, Sub: Submission of Un-audited Financial Results along with Limited Review Report thereon for the Quarter and half year ended on 30th September, 2026 Ref: Scrip Code: 524590 | Symbol: HEMORGANIC | ISIN: INE422G01015 In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Un-audited Financial Results along with Limited Review Report, by the Statutory Auditor of the Company, i.e., M/s. V S S B & Associates, Chartered Accountant, for the quarter and half year ended on 30 September, 2026. PFolera, sHe etmakoe Onortgea onfi cth Lei msaimteed a nd oblige. Vishwambar Kameshwar Singh Managing Director DIN: 09822587 HEMO ORGANIC LIMITED CIN - L24231GJ1992PLC018224 Address: Shop 1 to 3, First floor, Piyu Apartment Opp Electricity Sub Station & Mahesh Nagar, Nr. Radhika Chambers & Jay Amarnath Society, Nikol Gam Road, Uttamnagar, Ahmedabad, Gujarat, India – 382 350 Email ID: hemoorganic@gmail.com Website: www.hemoorganic.co Ph. No. 8238557874 Date: 17th October, 2026 BSE Limited Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400001. Dear Sir / Madam, Sub: Statement on deviation(s) / variation(s) in utilization of proceeds raised through Preferential Issue of convertible warrants, pursuant to Regulation 32 of SEBI (LODR) Regulations, 2015 (“SEBI Listing Regulations) for the quarter ended on September 30, 2026. Ref: Scrip Code: 524590 | Scrip Symbol: HEMORGANIC | ISIN: INE422G01015 Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the statement, in the prescribed format, confirming that there were no deviations or variations in the utilization of proceeds from the Preferential Issue of Convertible Warrants of the Company for the quarter ended September 30, 2026. The said statement was duly reviewed by the Audit Committee at its meeting held today, i.e., 17th October, 2026. You are requested to kindly take the above information on record. Thanking You, For, HEMO ORGANIC LIMITED VISHWAMBAR KAMESHWAR SINGH MANAGING DIRECTOR DIN: 09822587 STATEMENT OF DEVIATION OR VARIATION FOR PROCEEDS OF PREFERENTIAL ISSUE OF CONVERTIBLE WARRANTS: Name of listed entity Hemo Organic Limited Mode of Fund Raising Preferential Issue of Convertible Warrants Date of Raising Funds 17-09-2026 Amount Raised Rs. 2,76,25,000 Report filed for Quater ended 30th September, 2026 Monitoring Agency Not Applicable Monitoring Agency Name, if applicable Not Applicable Is there a Deviation / Variation in use of funds raised No If yes, whether the same is pursuant to change in terms of a Not Applicable contract or objects, which was approved by the Shareholders If Yes, Date of Shareholders Approval Not Applicable Explanation for the Deviation / Variation Not Applicable Comments of the Audit Committee after review None Comments of the auditors, if any None Objects for which funds have been raised in the Preferential Issue and details of deviation, if any, in the following table: (Rs. In lakhs) Sr. Object as Modified Original Modified Amount Unutilised Amount of Remarks, if any No. disclosed in Object, if Allocation allocation, utilised Amount Deviation/ the offer Any if Any Variation for document the Quarter 1 Working NA 318.75 NA 207.19 0 NA NA Capital Requirement 2 General NA 106.25 NA 69.06 0 NA NA Corporate Purpose 425.00 276.25 0 Deviation or variation could mean: (a) Deviation in the objects or purposes for which funds have been raised; or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or (c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc. FOR, HEMO ORGANIC LIMITED VISHWAMBAR KAMESHWAR SINGH MANAGING DIRECTOR DIN: 09822587 STATEMENT OF DEVIATION OR VARIATION FOR PROCEEDS OF PREFERENTIAL ISSUE OF CONVERTIBLE WARRANTS: Name of listed entity Hemo Organic Limited Mode of Fund Raising Preferential Issue of Convertible Warrants Date of Raising Funds 25-09-2026 Amount Raised Rs. 42,50,000 Report filed for Quater ended 30th September, 2026 Monitoring Agency Not Applicable Monitoring Agency Name, if applicable Not Applicable Is there a Deviation / Variation in use of funds raised No If yes, whether the same is pursuant to change in terms of a Not Applicable contract or objects, which was approved by the Shareholders If Yes, Date of Shareholders Approval Not Applicable Explanation for the Deviation / Variation Not Applicable Comments of the Audit Committee after review None Comments of the auditors, if any None Objects for which funds have been raised in the Preferential Issue and details of deviation, if any, in the following table: (Rs. In lakhs) Sr. Object as Modified Original Modified Amount Unutilised Amount of Remarks, if any No. disclosed in Object, if Allocation allocation, if utilised Amount Deviation/ the offer Any Any Variation for document the Quarter 1 Working NA 318.75 NA 31.87 - NA NA Capital Requirement 2 General NA 106.25 NA 9.54 1.09 NA An amount of Rs. Corporate 109,000 Purpose earmarked for General Corporate Purpose (“GCP”) remains unutilised and shall be deployed/adjusted as and when required towards General Corporate Purpose. 425.00 41.41 1.09 Notes: 1. On February 26, 2026, the Company allotted 34,00,000 Convertible Equity Share Warrants on a preferential basis to non-promoter allottees, pursuant to the approval granted by the shareholders at the Extra-Ordinary General Meeting held on January 07, 2026. Each warrant was issued at an issue price of ₹12.50/- (Rupees Twelve and Fifty Paise only), comprising a face value of ₹10.00/- and a premium of ₹2.50/- per warrant. 2. The Company had received an amount of ₹1,06,25,000/- (Rupees One Crore Six Lakh Twenty-Five Thousand only), representing 25% of the total issue price, from the allottees towards the subscription of warrants on February 26, 2026. The company has received the balance amount of ₹3,18,75,000/- (Rupees Three Crore Eighteen Lakh Seventy-Five Thousand only), representing the remaining 75% of the total issue price, during the quarter. 3. Upon receipt of the full issue consideration, the Company converted the aforesaid 34,00,000 Convertible Equity Share Warrants into an equivalent number of equity shares and allotted 34,00,000 equity shares to the respective warrant holders on September 25, 2026. The equity shares so allotted rank pari passu in all respects with the existing equity shares of the Company. Deviation or variation could mean: (a) Deviation in the objects or purposes for which funds have been raised; or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed; or (c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc. FOR, HEMO ORGANIC LIMITED VISHWAMBAR KAMESHWAR SINGH MANAGING DIRECTOR DIN: 09822587